This post was originally published on this site Fujifilm Medical Systems USA has expanded its breast cancer imaging toolbox by releasing a new tomosynthesis option for its ASPIRE Cristalle mammography technology, which improves accuracy of breast biopsy. The new Tomosynthesis Biopsy solution determines the three-dimensional coordinates of a suspicious lesion in the breast. According to…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
AVB-500 Plus Chemotherapy More Effective Than Chemo Alone in Platinum-resistant Patients, Early Trial Data Suggest
This post was originally published on this site Aravive‘s experimental treatment, AVB-500, in combination with chemotherapy appears to be more effective than chemotherapy alone at treating platinum-resistant ovarian cancer, preliminary results from a first group of patients taking part in a Phase 1b/2 trial show. The company will increase enrollment in this U.S. study to further…
AJMC Introduces 14-part Video Series on Multiple Myeloma Treatment
This post was originally published on this site A new video series by the American Journal of Managed Care (AJMC) features experts discussing issues related to multiple myeloma treatment. Called “A Review of the Treatment for Multiple Myeloma,” the 14-part educational series is the AJMC’s latest panel discussion. “During this educational video series, our panel of experts, led…
Cerdulatinib Alone or with Rituxan Effective in Previously Treated Follicular Lymphoma, Data Show
This post was originally published on this site Treatment with the oral therapy cerdulatinib alone or in combination with Rituxan (rituximab) shows durable efficacy, including some complete responses, in patients with follicular lymphoma who failed prior medications, according to early results of a Phase 2a trial. The study, “Rapid and Durable Responses with the SYK/JAK…
Upcoming Phase 2 Trial Will Test Opdivo-MTG201 Combo for Malignant Pleural Mesothelioma
This post was originally published on this site An upcoming Phase 2 trial will explore the safety and effectiveness of a combo therapy — Opdivo (nivolumab) and MTG201 – for the treatment of malignant pleural mesothelioma. The trial will soon be looking for participants who received prior chemotherapy. Mesothelioma is a rare type of cancer,…
Test Being Developed to Determine Risk of Recurrence in Triple-negative Breast Cancer
This post was originally published on this site A new test — based on genetic markers of immune response and with potential to be assayed in tumor biopsies — holds promise for identifying patients with triple-negative breast cancer (TNBC) who are at lower risk of disease recurrence, and therefore would benefit from less aggressive treatments.…
First Patients Dosed in Phase 2b Trial Testing Oral Docetaxel Treatment for Advanced Prostate Cancer
This post was originally published on this site A Phase 2b clinical trial evaluating ModraDoc006/r, Modra Pharmaceutical’s investigational oral treatment for metastatic castration-resistant prostate cancer, has started dosing patients, the company announced. ModraDoc006/r is a tablet formulation of the chemotherapy docetaxel. Doctors administer it with ritonavir, which increases the amount of docetaxel absorbed by the body.…
FDA Asked to Place Abexinostat, Possible Follicular Lymphoma Treatment, on Fast Track
This post was originally published on this site Xynomic Pharmaceuticals has filed a request with U.S. Food and Drug Administration (FDA) asking that abexinostat, its lead therapeutic candidate for relapsed or refractory follicular lymphoma, be given fast track designation. The designation is given to therapies that show potential to treat serious health conditions or those with unmet…
Prostate Cancer Therapy Zytiga Makes WHO’s Essential Medicines List
This post was originally published on this site Zytiga (abiraterone acetate), a kind of hormone therapy, has been added to the World Health Organization’s (WHO) Essential Medicines List for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Updated every two years since 1977, the publication focuses on recommendations for malignancies such as prostate cancer and other…
Pre-cancerous Lesions Do Not Always Lead to Ovarian Cancer, Study Finds
This post was originally published on this site Not all “pre-cancerous” ovarian lesions progress to full-fledged cancer, a new study reports. If confirmed, these results could allow for better identification of ovarian cancer at its very early stages, and potentially strengthen preventative care for this disease. The study was published in The Journal of Pathology and…
clonoSEQ Assay Approved in New York to Measure MRD in Myeloma, Other Blood Cancers
This post was originally published on this site The clonoSEQ Assay — a test that detects cancer cells present in very small numbers in a patient’s bone marrow, blood, or tissue sample — now is available to New York residents with multiple myeloma and other B-cell blood cancers. The announcement by Adaptive Biotechnologies follows an approval by…
Phase 1b Trial of Cabometyx-Tecentriq Combo in Solid Cancers Adding More Patients, Tumor Types
This post was originally published on this site Two initial patient groups have been expanded and four others added to a Phase 1b trial assessing the combination therapy Cabometyx (cabozantinib) and Tecentriq (atezolizumab) in people with locally advanced or metastatic solid tumors, Exelixis has announced. The multi-center, open-label COSMIC-021 trial (NCT03170960) is evaluating the safety, tolerability, preliminary efficacy,…